Pfizer’s RSV Vaccine Effective in Keeping Infants Out of Hospital in Phase 3 Trial

Pfizer announced that its respiratory syncytial virus (RSV) vaccine showed an efficacy of 82 percent against hospitalization in infants under 90 days old, and 69 percent among those younger than six months, according to a press release from the company.